Patient's question:
Reward 100 Health CoinsFrom Hebei, China,
Thank you to the doctor for answering my question quickly – how to treat and prevent it.
Doctor's answer:
Disease Analysis: Hello! The treatment and prevention methods for neonatal hemolytic disease are as follows:1. Antenatal Treatment
(1) Plasma exchange should be considered when the's blood contains Rh antibodies at a titer of 1:64, to remove Rh blood group antibodies.
(2) Intrauterine blood transfusion can be performed if the fetus has edema or Hb < 80g/L, and the lungs are immature.
(3) Pregnant women should take phenobarbital 60mg/day orally 1–2 weeks before delivery to induce the production of fetal glucuronidase.
(4) If the amniotic fluid bilirubin level is significantly elevated and the lecithin/sphingomyelin (L/S) ratio is greater than 2, preterm delivery should be considered to prevent further development of fetal edema or stillbirth.
2. Neonatal Treatment
(1) Medication:
① Hepatic enzyme inducers: Phenobarbital is commonly used.
Dosage: Start oral administration 24 hours after birth, 5mg/kg/day, divided into 2–3 doses, for 4–5 days. Due to its slow onset of action, it is less effective after jaundice has developed.
② Infusion of albumin or plasma: Increases blood albumin concentration, enhances albumin binding with bilirubin, reduces the level of free bilirubin in the serum, and thus decreases the risk of kernicterus.
Dosage: Albumin 1g/(kg·dose) via intravenous drip, or plasma 20–30ml/dose via intravenous drip.
③ Intravenous infusion of immunoglobulin: Early use is more effective. Administer 1g/kg via intravenous drip over 6–8 hours.
④ Correct hypoxia and acidosis: Acidosis affects the binding of albumin and bilirubin. Administer 3–5ml/(kg·dose) of 5% sodium bicarbonate diluted and infused intravenously.
(2) Phototherapy: This is currently the most widely used and safest effective measure. It oxidizes bilirubin at a depth of 2mm in the skin into non-toxic water-soluble products, which are then excreted through bile and urine. Full-term infants with bilirubin > 205μmol/L (12mg/dL) (various pathological jaundices) and preterm infants with bilirubin > 171μmol/L (10mg/dL) can undergo phototherapy. If neonatal hemolytic disease is confirmed, phototherapy can be initiated at the first sign of jaundice and also used as adjunctive treatment before and after exchange transfusion.
(3) Exchange transfusion: In neonatal hemolytic disease, exchange transfusion can remove some free antibodies and sensitized red blood cells in the blood, reducing hemolysis; exchange a large amount of bilirubin in the blood to prevent bilirubin encephalopathy; correct anemia, improve oxygen-carrying capacity, and prevent heart failure.
Indications: Most Rh hemolytic diseases and some severe ABO hemolytic diseases. Exchange transfusion should be performed if any of the following conditions are met:
① Prenatal diagnosis is confirmed, and umbilical cord blood total bilirubin > 68μmol/L (4mg/dL), hemoglobin < 120g/L, with edema, hepatosplenomegaly, and heart failure (severe symptoms);
② Bilirubin rises by > 12μmol/L (0.7mg/dL) per hour within 12 hours after birth;
③ Total bilirubin has reached 342μmol/L (20mg/dL);
④ Early signs of bilirubin encephalopathy (lethargy, feeding difficulties, weak sucking, decreased or absent reflexes, hypotonia) regardless of serum bilirubin levels;
⑤ For small preterm infants, those with hypoxia and acidosis, or those with severe hemolysis in previous pregnancies, the indication should be appropriately relaxed.
Blood type for exchange: Rh hemolytic disease should use Rh-compatible blood with the mother, and ABO hemolytic disease should use ABO-compatible blood with the infant. In emergencies or when blood is unavailable, O-type blood may be used. For ABO hemolytic disease where the mother is O-type and the child is A or B-type, AB-type plasma mixed with O-type red blood cells is preferred, or low-titer anti-A or anti-B O-type blood or blood compatible with the infant may be used. For significant anemia and heart failure, half-diluted concentrated blood can be used.
Exchange volume: Generally twice the infant's blood volume (approximately 150–180ml/kg), which can remove about 85% of sensitized red blood cells and 60% of bilirubin and antibodies.
3. Prevention
(1) Rh-negative pregnant women should receive intramuscular injection of anti-D-IgG 300μg within 3 days of miscarriage or delivery of an Rh-positive infant to neutralize 10ml of fetal blood and prevent the mother from becoming sensitized.
(2) Rh-negative women should also use the same dose of prevention after miscarriage, amniocentesis, antenatal bleeding, or ectopic pregnancy with Rh-positive blood transfusion.